Document is current
Any future updates will be listed below
-
Authors
Hiraizumi, Masahiro https://orcid.org/0000-0002-4340-2937
Athukoralage, Januka S.
Perry, Nicholas T. https://orcid.org/0000-0002-1702-4178
Tsujimoto, Eisuke
Shiojiri, Nami
Nagahata, Naoto
Lee, Lauren
Sun, Gwanggyu
Durrant, Matthew G.
Chandrasekaran, Sita S.
Konermann, Silvana https://orcid.org/0000-0001-7915-1685
Yamashita, Keitaro https://orcid.org/0000-0002-5442-7582
Hsu, Patrick D. https://orcid.org/0000-0002-9380-2648
Nishimasu, Hiroshi https://orcid.org/0000-0002-2505-1416
- License Information
-
More Information
Article History
Received: 5 November 2025
Accepted: 10 July 2026
First Online: 12 August 2026
Ethics
Competing interests: P.D.H. acknowledges outside interest in Stylus Medicine, Terrain Biosciences and Monet AI as a co-founder, serves on the board of directors at Stylus Medicine and the scientific advisory board at Amgen, and is a venture partner at Thrive Capital. M.G.D. acknowledges outside interest in Stylus Medicine. N.T.P., M.G.D. and P.D.H. are inventors on patent application no. PCT/US23/82192 submitted by the Arc Institute that covers bridge recombinase in human cells. M.H., J.S.A., N.T.P., M.G.D., P.D.H. and H.N. are inventors on patent application no. PCT/US25/12632 submitted by the Arc Institute that covers bRNA engineering. All other authors declare no competing interests.
